KIT N505R

CI-VAR-00002910Explore in graph →CIViC 3238

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
KIT N505R	Imatinib	Predictive	D	Does Not Support Sensitivity Response	4	submitted	EID8963 This study analyzed recurring somatic oncogenic mutation located in the C-terminal Ig-like domain (D5) of the KIT ectodomain and showed that some render KIT tyrosine kinase activity constitutively act… (full text at CIViC) PMID 25544564 · Reshetnyak et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.